Mesoblast Limited (MESO) vs Vir Biotechnology, Inc. (VIR)

Mesoblast Limited and Vir Biotechnology, Inc. are both Biotechnology companies. Mesoblast Limited and Vir Biotechnology, Inc. are of similar size ($1.8B and $1.8B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,495.9% against −26.5%. Vir Biotechnology, Inc. has the higher net margin (−83.0% vs −1,091.7%) and the lower return on invested capital (−39.1% vs 0.00%). Across the 18 metrics below, Mesoblast Limited leads on 9 and Vir Biotechnology, Inc. on 9.

Valuation

Metric MESO VIR Biotechnology median
P/E n/m n/m 8.50
P/S 137.69 5.51 9.71
P/B 1.80 1.70 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 137.28 3.75 9.21
Earnings yield (8.43%) (18.57%) (33.15%)
Free cash flow yield (8.17%) (12.19%) (25.50%)

Profitability

Metric MESO VIR Biotechnology median
Gross margin (269.72%) 100.00% 65.16%
Operating margin (826.28%) (92.40%) 0.00%
Net margin (1,091.71%) (83.00%) 0.00%
Free cash flow margin 0.00% (67.17%) 0.00%
Return on equity 0.00% (26.08%) (56.36%)
Return on assets 0.00% (20.91%) (48.04%)
Return on invested capital 0.00% (39.10%) 0.00%

Growth

Metric MESO VIR Biotechnology median
Revenue growth (TTM) (26.54%) 1,495.93% 6.02%
EPS growth (last fiscal year) 48.24% 17.49% 30.26%
Revenue growth, 5-year CAGR 74.39% (2.14%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO VIR Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 6.04 4.72
Net debt to EBITDA (0.67) 1.02 0.96

Dividend

Metric MESO VIR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MESO VIR Biotechnology median
Market cap 1.81b 1.77b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack